Company:  AYTU BIOSCIENCE, INC (AYTU)
Form Type:  10-Q
Filing Date:  5/14/2019 
CIK:  0001385818 
Address:  373 INVERNESS PARKWAY
SUITE 206
 
City, State, Zip:  ENGLEWOOD, Colorado 80112 
Telephone:  (720) 437-6580 
Fiscal Year:  06/30 
Last Trade
Last Trade: 
$1.50  
Change: 
0.0405 (2.77%)  
Trade Time: 
01:43 PM EST  
Market Cap: 
$24.99M
Trade AYTU now with

© 2019  
Description of Business
We are a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. We have multiple approved products on the market, and we seek to build a portfolio of novel therapeutics that serve large medical needs, across a range of conditions, through our in-house commercial team. Our commercial infrastructure consists of a U.S.-based specialty sales force and an international distribution network with presence in approximately fifty countries. We are currently concentrating on hypogonadism, male infertility and, recently, insomnia and plan to expand into other indications for which we believe there are significant medical needs. We acquired exclusive U.S. rights to Natesto® (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel, and we launched Natesto in the U.S. with our direct sales force in late summer 2016.
Register and access this filing in:     
  FORM 10-Q
    PART I-FINANCIAL INFORMATION
      Item 1. Consolidated Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Consolidated Financial Statements
          Note 12 - Subsequent Events
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures.
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings.
      Item 1A. Risk Factors.
      Item 2. Unregistered Sales of Securities and Use of Proceeds.
      Item 3. Defaults Upon Senior Securities.
      Item 4. Mine Safety Disclosures.
      Item 5. Other Information.
      Item 6. Exhibits.
    SIGNATURES
  EXHIBIT 10.1
  EXHIBIT 10.2
  EXHIBIT 10.3
  EXHIBIT 31.1
    Certification by Chief Executive Officer
  EXHIBIT 31.2
    Certification by Chief Financial Officer
  EXHIBIT 32.1
    Certification Pursuant to 18 U.S.C. Section 1350, as Adopted